LILRB4,骨髓细胞的免疫检查点。

IF 1.5 Q3 HEMATOLOGY
血液科学(英文) Pub Date : 2022-05-17 eCollection Date: 2022-04-01 DOI:10.1097/BS9.0000000000000109
Ting Yang, Yixin Qian, Xiaoting Liang, Jianbo Wu, Ming Zou, Mi Deng
{"title":"LILRB4,骨髓细胞的免疫检查点。","authors":"Ting Yang,&nbsp;Yixin Qian,&nbsp;Xiaoting Liang,&nbsp;Jianbo Wu,&nbsp;Ming Zou,&nbsp;Mi Deng","doi":"10.1097/BS9.0000000000000109","DOIUrl":null,"url":null,"abstract":"<p><p>Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malignant human cells of myeloid origin. By binding to ligands, LILRB4 is activated and subsequently recruits adaptors to cytoplasmic immunoreceptor tyrosine inhibitory motifs to initiate different signaling cascades, thus playing an important role in physiological and pathological conditions, including autoimmune diseases, microbial infections, and cancers. In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In disease-associated or malignant myeloid cells, LILRB4 is significantly correlated with disease severity or patient survival and suppresses T cells, thereby participating in the pathogenesis of various diseases. In summary, LILRB4 functions as an immune checkpoint on myeloid cells and may be a promising therapeutic target for various human immune diseases, especially for cancer immunotherapy.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/ff/bls-4-49.PMC9362873.pdf","citationCount":"2","resultStr":"{\"title\":\"LILRB4, an immune checkpoint on myeloid cells.\",\"authors\":\"Ting Yang,&nbsp;Yixin Qian,&nbsp;Xiaoting Liang,&nbsp;Jianbo Wu,&nbsp;Ming Zou,&nbsp;Mi Deng\",\"doi\":\"10.1097/BS9.0000000000000109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malignant human cells of myeloid origin. By binding to ligands, LILRB4 is activated and subsequently recruits adaptors to cytoplasmic immunoreceptor tyrosine inhibitory motifs to initiate different signaling cascades, thus playing an important role in physiological and pathological conditions, including autoimmune diseases, microbial infections, and cancers. In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In disease-associated or malignant myeloid cells, LILRB4 is significantly correlated with disease severity or patient survival and suppresses T cells, thereby participating in the pathogenesis of various diseases. In summary, LILRB4 functions as an immune checkpoint on myeloid cells and may be a promising therapeutic target for various human immune diseases, especially for cancer immunotherapy.</p>\",\"PeriodicalId\":67343,\"journal\":{\"name\":\"血液科学(英文)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-05-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/ff/bls-4-49.PMC9362873.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"血液科学(英文)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/BS9.0000000000000109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

白细胞免疫球蛋白样受体B4 (LILRB4)是LILR家族中的一种抑制性受体,主要表达于正常和恶性人髓系细胞。通过与配体结合,LILRB4被激活,随后向细胞质免疫受体酪氨酸抑制基序募集适配体,启动不同的信号级联反应,从而在自身免疫性疾病、微生物感染和癌症等生理和病理条件中发挥重要作用。在正常骨髓细胞中,LILRB4调节细胞的内在活化和分化。在疾病相关或恶性髓系细胞中,LILRB4与疾病严重程度或患者生存显著相关,抑制T细胞,从而参与多种疾病的发病机制。综上所述,LILRB4作为骨髓细胞的免疫检查点,可能是多种人类免疫疾病,特别是癌症免疫治疗的有希望的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

LILRB4, an immune checkpoint on myeloid cells.

LILRB4, an immune checkpoint on myeloid cells.

Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an inhibitory receptor in the LILR family mainly expressed on normal and malignant human cells of myeloid origin. By binding to ligands, LILRB4 is activated and subsequently recruits adaptors to cytoplasmic immunoreceptor tyrosine inhibitory motifs to initiate different signaling cascades, thus playing an important role in physiological and pathological conditions, including autoimmune diseases, microbial infections, and cancers. In normal myeloid cells, LILRB4 regulates intrinsic cell activation and differentiation. In disease-associated or malignant myeloid cells, LILRB4 is significantly correlated with disease severity or patient survival and suppresses T cells, thereby participating in the pathogenesis of various diseases. In summary, LILRB4 functions as an immune checkpoint on myeloid cells and may be a promising therapeutic target for various human immune diseases, especially for cancer immunotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信